Supreme Court Examines Limits of “Skinny Label” Marketing in Hikma Case

The Supreme Court of the United States has heard oral arguments in the ongoing dispute between Hikma Pharmaceuticals and Amarin Pharma, focusing on the legal boundaries of marketing generic drugs under a “skinny label.” 

The case centres on Hikma’s launch of a generic version of Vascepa (icosapent ethyl), approved only for a limited use, while broader uses of the branded drug remain protected by patent. The key legal question is whether Hikma’s references to its product as a “generic version” of Vascepa, along with the use of publicly available information about the branded drug, could be seen as encouraging doctors to prescribe the generic for patented uses. 

Under the Hatch-Waxman Act, generic manufacturers are permitted to market drugs for unpatented uses but are prohibited from promoting patented indications. This framework relies on “skinny labeling,” where patented uses are removed from the product label. 

During the hearing, concerns were raised about how far generic companies can go in describing their products without risking liability. Representatives supporting Hikma argued that broad liability could undermine the purpose of the Hatch-Waxman system by discouraging generic entry. In contrast, Amarin maintained that Hikma’s specific marketing language crossed the line and justified legal action. 

The justices did not indicate a clear position, though some acknowledged the potential impact on the generic drug market if liability standards are expanded. 

The outcome of the case could clarify how courts define “inducement” in patent law and shape how generics communicate about their products going forward.